Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
327.33
+11.19 (3.54%)
Apr 13, 2026, 10:43 AM EDT - Market open
PRAX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
168
Market Cap
9.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 8.55M | 6.11M | 249.53% |
| Dec 31, 2023 | 2.45M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.22B |
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
PRAX News
- 7 days ago - Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial - Benzinga
- 7 days ago - Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewsWire
- 10 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs - GlobeNewsWire
- 7 weeks ago - Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
- 7 weeks ago - Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders - Business Wire